OAB Treatment VL

Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR - Beyond the Abstract Details Patient perception of meaningful reductions in bothersome symptoms of overactive bladder (OAB) is lacking. In the phase 3 EMPOWUR trial, vibegron significantly reduced the average daily number of micturitions, urgency episodes, and urge urinary incontinence (UUI) episodes vs placebo. This analysis assessed the meaningfulness of reductions in clinical endpoints observed in EMPOWUR using the patient...
The Effects of Vibegron on Ambulatory Blood Pressure in Patients With Overactive Bladder - Michael A. Weber Details Diane Newman is joined by Michael Weber discussing a novel medication for the treatment of overactive bladder and a study Dr Weber presented at the AUA 2021 Annual Meeting. Vibegron, a beta-3 receptor agonist is used for the treatment of overactive bladder. Adults with overactive bladder in the age range, 40 to 75, were randomized to treatment either with Vibegron 75 milligrams per day or placebo....

Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR - Beyond the Abstract